BEVERLY, Mass. and TORONTO, March 21, 2024 (GLOBE NEWSWIRE) — Hamilton Thorne Ltd. (TSX: HTL) is a leading manufacturer of precision instruments, laboratory equipment, consumables, software and services for assisted reproductive technology (ART). is a major provider of , research, and cell biology market, announced today that it will announce its financial results for the three and 12 months ending December 31, 2023, before the market open on Wednesday, March 27, 2024. . Press releases will be accompanied by financial information. It will be published on our websites www.hamiltonthorne.ltd and www.sedar.com.
The Company plans to hold a conference call at 9:00 a.m. ET on the same day to review the highlights of the results.
All interested parties may join the conference call by dialing toll-free 1-833-366-1126 in North America or 1-412-317-0703 elsewhere and requesting the “Hamilton Thorne Teleconference.” can. Our latest investor presentation and call recording will be available on Hamilton Thorne's website immediately following the call.
About Hamilton Thorne Co., Ltd. (www.hamiltonthorn.ltd)
Hamilton Thorne provides precision instruments, laboratory equipment, and equipment that reduce costs, increase productivity, improve outcomes, and enable breakthroughs in the assisted reproductive technology (ART), research, and cell biology markets. We are one of the world's leading providers of consumables, software and services. Through a growing global sales force and distributors, Hamilton Thorne offers products and services under the Hamilton Thorne, GineMed, Planar, TechEvent, IVFtech, Microptik, Ginetics, and Embryotech Laboratories brands. We are selling. Hamilton Thorne Ltd.'s customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research facilities.
Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.
For more information, please contact us below.
